Stocks Health care ZEOX
OTC · Health careZeo ScientifiX, Inc. (ZEOX)
Zeo ScientifiX, Inc. brought in $7M of revenue over the twelve months to April 30, 2026, up 52.8% from a year earlier. It posted a net loss of $3.9M. In fiscal 2024 capital spending exceeded operating cash flow by $741K. At April 30, 2026 it held $1.8M in cash against $247K of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on June 15, 2026.
Watch ZEOX in 60 secondsWhat Zeo ScientifiX, Inc. does
Zeo ScientifiX, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on OTC under the ticker ZEOX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2024 | $5.2M | -$5.5M | -$0.86 | -$741K |
| 2024 | $4.6M | -$4.7M | -$0.74 | n/a |
| 2023 | $4.6M | -$7M | -$0.99 | -$2.2M |
| 2022 | $6.5M | -$8.9M | -$1.56 | -$4M |
| 2021 | $5.6M | -$12.8M | -$0.01 | -$3.1M |
| 2020 | $3.1M | -$12.6M | -$0.02 | -$2M |
Full financial statements: income, balance sheet and cash flow
Where ZEOX ranks in Health care
Latest SEC filings
What Zeo ScientifiX, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 15, 2026
- September 15, 2026Other event 8-K
- September 14, 2026Late quarterly report notice NT 10-Q
- September 1, 2026Other event 8-K
- August 4, 2026Other event 8-K
- July 24, 2026Activist stake changed SCHEDULE 13D/A
- July 24, 2026Activist stake changed SCHEDULE 13D/A
- July 24, 2026Passive stake changed SCHEDULE 13G/A
- July 24, 2026
- July 21, 2026Other event 8-K
Insider trades
What the people running Zeo ScientifiX, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| January 14, 2026 | Shapiro George CraigChief Medical Officer, Director | Received as pay | 175,000 | - |
| January 14, 2026 | Bothwell Ian TCEO & CFO, Director, 10% owner | Received as pay | 175,000 | - |
| January 14, 2026 | Grey Wendy10% owner | Received as payindirect | 175,000 | - |
Who owns ZEOX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Grey Wendy13D, may seek influence with 1 related filers | 23.88% | July 24, 2026 |
| Ian T Bothwell13D, may seek influence | 20.6% | July 24, 2026 |
| Shapiro George Craig13G, passive | 15.1% | July 24, 2026 |
| Skycrest Holdings, LLC13D, may seek influence | 7.04% | October 20, 2025 |
Largest institutional holders
Insiders
3 insiders reported holding 1,918,115 shares in total, about $2.6M at the last price.
| Holder | Shares |
|---|---|
| Bothwell Ian TCEO & CFO, Director, 10% owner | 915,094 |
| Shapiro George CraigChief Medical Officer, Director | 578,021 |
| Grey Wendy10% owner | 425,000425,000 held indirectly |
Questions about ZEOX
What does Zeo ScientifiX, Inc. do?
Zeo ScientifiX, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on OTC under the ticker ZEOX.
Is Zeo ScientifiX, Inc. profitable?
No. Over the twelve months to April 30, 2026 it reported a net loss of $3.9M on revenue of $7M.
How much revenue does Zeo ScientifiX, Inc. make?
Over the twelve months to April 30, 2026 Zeo ScientifiX, Inc. reported revenue of $7M. That is 52.8% more than a year earlier.
When did Zeo ScientifiX, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on June 15, 2026. It covers the period to April 30, 2026. Its newest filing of any kind is the bylaws or fiscal year changed from September 15, 2026.
Similar companies
Compare ZEOX with
Follow ZEOX
Get an email when Zeo ScientifiX, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow ZEOX: get an email when it filesWhere the numbers come from
Financial figures are the values Zeo ScientifiX, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.